IL120382A - Extended release formulation of venlafaxine hydrochloride - Google Patents

Extended release formulation of venlafaxine hydrochloride

Info

Publication number
IL120382A
IL120382A IL12038297A IL12038297A IL120382A IL 120382 A IL120382 A IL 120382A IL 12038297 A IL12038297 A IL 12038297A IL 12038297 A IL12038297 A IL 12038297A IL 120382 A IL120382 A IL 120382A
Authority
IL
Israel
Prior art keywords
extended release
venlafaxine hydrochloride
release formulation
antidepressant
nausea
Prior art date
Application number
IL12038297A
Other languages
English (en)
Other versions
IL120382A0 (en
Inventor
Deborah Marie Sherman
John Clifton Clark
John Ulrich Lamer
Stephen Andrew White
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21762972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL120382(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Priority to IL15145097A priority Critical patent/IL151450A/xx
Publication of IL120382A0 publication Critical patent/IL120382A0/xx
Publication of IL120382A publication Critical patent/IL120382A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
IL12038297A 1996-03-25 1997-03-06 Extended release formulation of venlafaxine hydrochloride IL120382A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL15145097A IL151450A (en) 1996-03-25 1997-03-06 Extended release formulation of venlafaxine hydrochloride

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1400696P 1996-03-25 1996-03-25

Publications (2)

Publication Number Publication Date
IL120382A0 IL120382A0 (en) 1997-07-13
IL120382A true IL120382A (en) 2003-06-24

Family

ID=21762972

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12038297A IL120382A (en) 1996-03-25 1997-03-06 Extended release formulation of venlafaxine hydrochloride

Country Status (34)

Country Link
EP (2) EP0797991B1 (de)
JP (2) JP4771565B2 (de)
KR (1) KR101096512B1 (de)
CN (2) CN1090018C (de)
AR (1) AR006519A1 (de)
AT (1) ATE257011T1 (de)
AU (1) AU727653B2 (de)
BR (1) BR9701304A (de)
CA (1) CA2199778C (de)
CO (1) CO4761054A1 (de)
CY (1) CY2442B1 (de)
CZ (1) CZ291637B6 (de)
DE (1) DE69727000T2 (de)
DK (1) DK0797991T3 (de)
EG (1) EG24198A (de)
ES (1) ES2210454T3 (de)
HK (1) HK1056686A1 (de)
HU (1) HU224617B1 (de)
IL (1) IL120382A (de)
IN (1) IN187337B (de)
NO (2) NO320355B1 (de)
NZ (1) NZ314442A (de)
PA (1) PA8426401A1 (de)
PE (1) PE57198A1 (de)
PL (2) PL195564B1 (de)
PT (1) PT797991E (de)
RU (1) RU2176912C2 (de)
SK (1) SK281530B6 (de)
SV (1) SV1997000015A (de)
TR (1) TR199700190A2 (de)
TW (1) TW493993B (de)
UA (1) UA44904C2 (de)
UY (1) UY24613A1 (de)
ZA (1) ZA972403B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8105627B2 (en) 2003-05-02 2012-01-31 Dexcel Ltd. Extended release venlafaxine tablet formulation

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
JP3379461B2 (ja) * 1998-08-06 2003-02-24 三菱電機株式会社 コア部材の積層金型装置、コア部材の積層方法および電動機
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
CA2698347A1 (en) * 1999-05-20 2000-11-30 Elan Pharma International Limited Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
ES2162746B1 (es) * 1999-10-21 2003-02-16 Lipotec Sa Microcapsulas para la estabilizacion de productos cosmeticos, farmaceuticos o de alimentacion.
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
CZ20031298A3 (cs) * 2000-10-19 2003-10-15 Teva Pharmaceutical Industries Ltd. Způsob přípravy krystalické báze venlafaxinu a nových polymorfů hydrochloridu venlafaxinu
SE0102886D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102888D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
HUP0104872A3 (en) * 2001-11-13 2004-04-28 Egis Gyogyszergyar Nyilvanosan New polymorphic forms of venlafaxine, process for their preparation, pharmaceutical compositions containing them and their use
WO2003082805A1 (en) * 2002-03-28 2003-10-09 Synthon B.V. Low water-soluble venlafaxine salts
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations
AR039163A1 (es) 2002-03-28 2005-02-09 Synthon Bv Besilato de venlafaxina
US20060246132A1 (en) * 2003-02-07 2006-11-02 Fjalar Johannsson Sustained release formulations of venlafaxine
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
IN2003MU00504A (de) * 2003-06-05 2005-05-13 Alembic Ltd
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
SI1502587T1 (sl) 2003-07-30 2007-02-28 Pharmathen Sa Formulacija z zadrzevanim sproscanjem za Venlafaxin hidroklorid
WO2005048979A2 (en) * 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
EP1523979A1 (de) * 2003-10-13 2005-04-20 Wyeth Darreichungsform mit verlängerter Freisetzung
EP1523981A1 (de) * 2003-10-13 2005-04-20 Wyeth Venlafaxine-Zubereitungen mit verlängerter Freisetzung
DE10359154A1 (de) 2003-12-16 2005-07-28 Krka Tovarna Zdravil, D.D. Verfahren zur Herstellung von Venlafaxin und Venlafaxinhydrochlorid der Form I
PL1711169T3 (pl) 2004-02-04 2007-10-31 Alembic Ltd Powlekane tabletki chlorowodorku wenlafaksyny o wydłużonym czasie uwalniania
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CN100463676C (zh) * 2004-11-11 2009-02-25 成都康弘药业集团股份有限公司 一种盐酸文拉法辛控释片制剂及其制备方法
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2648280C (en) * 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
PL2010158T3 (pl) 2006-04-26 2016-09-30 Formulacje o kontrolowanym uwalnianiu zawierające niepowlekaną odrębną jednostkę(-i) i macierz o przedłużonym uwalnianiu
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
KR100791194B1 (ko) * 2006-06-12 2008-01-02 코오롱제약주식회사 염산 벤라팍신의 경구 투여용 서방성 펠렛 및 그 제조방법
BR112012019374B1 (pt) * 2010-02-03 2022-01-11 Pharma Two B Ltd Composição farmacêutica oral e uso de um agente ativo para a preparação de uma composição farmacêutica oral para o tratamento de doenças neurodegenerativas
WO2011132008A2 (en) 2010-04-22 2011-10-27 EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság Controlled release pharmaceutical composition
US9789093B2 (en) 2011-01-31 2017-10-17 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
CN103893151B (zh) * 2012-12-31 2018-04-27 石药集团中奇制药技术（石家庄）有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
CN114288273B (zh) * 2022-02-11 2022-10-18 桂林华信制药有限公司 一种盐酸文拉法辛缓释胶囊及其生产工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
IE56324B1 (en) * 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
IE60311B1 (en) 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
DK0639374T3 (da) * 1993-06-28 2002-05-06 American Home Prod Nye behandlingsmetoder ved anvendelse af phenethylderivater
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8105627B2 (en) 2003-05-02 2012-01-31 Dexcel Ltd. Extended release venlafaxine tablet formulation

Also Published As

Publication number Publication date
JP2008156374A (ja) 2008-07-10
HK1056686A1 (en) 2004-02-27
KR970064599A (ko) 1997-10-13
NO320355B1 (no) 2005-11-28
PE57198A1 (es) 1998-10-10
HUP9700589A3 (en) 2001-03-28
CN1090018C (zh) 2002-09-04
EG24198A (en) 2008-10-14
PT797991E (pt) 2004-05-31
SV1997000015A (es) 1997-08-13
AR006519A1 (es) 1999-09-08
CO4761054A1 (es) 1999-04-27
ES2210454T3 (es) 2004-07-01
PL318954A1 (en) 1997-09-29
CZ77297A3 (en) 1997-11-12
SK30197A3 (en) 1997-10-08
AU1640097A (en) 1997-10-02
HU9700589D0 (en) 1997-05-28
UY24613A1 (es) 2000-09-29
NZ314442A (en) 1999-06-29
PA8426401A1 (es) 2000-05-24
HU224617B1 (hu) 2005-11-28
TR199700190A2 (xx) 1997-10-21
AU727653B2 (en) 2000-12-21
KR101096512B1 (ko) 2014-11-28
CN1164389A (zh) 1997-11-12
NO971206L (no) 1997-09-26
CZ291637B6 (cs) 2003-04-16
DK0797991T3 (da) 2004-04-05
NO971206D0 (no) 1997-03-14
CY2442B1 (en) 2004-11-12
ZA972403B (en) 1998-09-21
BR9701304A (pt) 1998-09-29
JP4771565B2 (ja) 2011-09-14
EP0797991A1 (de) 1997-10-01
UA44904C2 (uk) 2002-03-15
EP0797991B1 (de) 2004-01-02
CN1403077A (zh) 2003-03-19
CA2199778C (en) 2005-12-20
SK281530B6 (sk) 2001-04-09
RU2176912C2 (ru) 2001-12-20
MX9701873A (es) 1997-09-30
NO20050379L (no) 1997-09-26
EP2881110A1 (de) 2015-06-10
IL120382A0 (en) 1997-07-13
PL195564B1 (pl) 2007-10-31
DE69727000T2 (de) 2004-06-09
ATE257011T1 (de) 2004-01-15
PL188444B1 (pl) 2005-02-28
JPH107552A (ja) 1998-01-13
TW493993B (en) 2002-07-11
CA2199778A1 (en) 1997-09-25
DE69727000D1 (de) 2004-02-05
HUP9700589A2 (en) 1997-09-29
IN187337B (de) 2002-03-30

Similar Documents

Publication Publication Date Title
IL120382A (en) Extended release formulation of venlafaxine hydrochloride
AU6517496A (en) Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole
WO1994027589A3 (en) Antidepressant dosage form
NZ504460A (en) Sustained release formulations containing venlafaxine
HK1010447A1 (en) Tramadol salt containing medicaments with sustained release of the active ingredient
ES2161882T3 (es) Forma de dosificacion oral de metoprolol, de una vez al dia.
HUP9601566A3 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
CA2427815A1 (en) Controlled release hydrocodone formulations
ZA962536B (en) Pharmaceutical composition for transdermal administration.
AU6136199A (en) Dosage form comprising therapeutic formulation
NO20053104D0 (no) Oral, analgesisk doseringsform med forlenget frigivelse for administrering ±n gang pr. dag.
EP0645136A3 (de) Pharmazeutisches Präparat des Typs: physiologisch aktive Substanz mit verlängerter Freisetzung.
WO2000041681A3 (de) ARZNEIFORMULIERUNGEN ENTHALTEND EIN OPIOID UND EINEN α-AGONISTEN
GEP20063882B (en) Dosage regimen and pharmaceutical composition for emergency contraception
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
HK1067299A1 (en) Pharmaceutical compositions containing terbinafineand use thereof
RS50298B (sr) Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
AU5139596A (en) Pharmaceutical matrix pellets, tablets and composition for the preparation thereof
GEP20043377B (en) Pharmaceutical Complex
IL116747A (en) Use of 3,4-diphenyl chromans for the preparation of pharmaceutical compositions for the treatment of gynaecomastia
ECSP972046A (es) Formula de liberacion prolongada
MX9606041A (es) Forma de dosificacion de rapida disolucion.